07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Alligator Bioscience, J&J deal

Alligator granted Johnson & Johnson’s Janssen Biotech Inc. unit exclusive, worldwide rights to develop and commercialize ADC-1013 . Alligator expects to complete a Phase I trial of the antibody-based CD40 receptor activator immunotherapy in solid...
01:46 , Aug 13, 2015 |  BC Extra  |  Company News

Janssen snaps up Alligator's immunotherapy candidate

Alligator Bioscience AB (Lund, Sweden) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to cancer immunotherapy candidate ADC-1013 . Under a separate agreement, J&J's venture arm Johnson & Johnson...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Alligator Bioscience, BioInvent deal

BioInvent sold back all rights to preclinical cancer compound ADC-1013 to former partner Alligator for an undisclosed sum. BioInvent has successfully manufactured the antibody-based CD40 receptor activator immunotherapy and will fulfill the remaining activities required...